Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought
to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute …

Background and Methods. Specific chromosomal abnormalities have been shown to affect
the overall survival of patients with acute leukemia, but the possibility that specific …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment
in fit patients (ie, those with a low burden of coexisting conditions) with advanced chronic …

… Knauf, Ribosepharm, Germany and Mundipharma, Germany Hans-Joerg Fricke,
Ribosepharm, Germany; Marco Montillo, Mundipharma Italy Research Funding: Peter Klein …

Mounting evidence indicates that grouping of chronic lymphocytic leukemia (CLL) into
distinct subsets with stereotyped BCRs is functionally and prognostically relevant. However, …

Purpose APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of
unfolded wild-type or mutant p53. The main aims of this first-in-human trial were to determine …

This phase 2 study evaluated the safety and efficacy of alemtuzumab in 22 patients with
advanced mycosis fungoides/Sézary syndrome (MF/SS). Most patients had stage III or IV disease…

Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …

In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid
leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of …

The immunoglobulin variable heavy chain (IgV H ) gene mutation status is an important
prognostic factor in chronic lymphocytic leukemia (CLL), since cases with mutated V H genes …